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Background: New research criteria for diagnosing Alzheimer’s disease (AD) in the mild
cognitive impairment stage (MCI-AD) incorporate biomarkers to assign a level of certainty
to the diagnosis. Structural MRI is widely available but greatly under-utilized for assessing
atrophy of structures affected in early AD, such as the hippocampus (HP), because the
quantification of HP volumes (HP-v) requires special expertise, and normative values have
not been established.
Methods: Elderly subjects (n = 273) from the Florida ADRC were classified as having
no cognitive impairment (cognitively normal, CN), amnestic mild cognitive impairment
(aMCI) or AD. Volumes for the hippocampus (HP-v) were measured on structural MRI
scans. A validated visual rating system for measuring medial temporal atrophy (VRS-MTA),
including hippocampal, entorhinal cortex and perirhinal cortex atrophy was employed. The
participants were subdivided into younger (less than or equal to 75 years of age) and older
(greater than 75 years of age) subgroups.
Results: Volumetric and VRS-MTA measures were equivalent in predicting classification
of CN vs. aMCI for older (area under the receiver operator curves [aROC]: 0.652 vs.
0.723) and younger subjects (aROC: 0.764 vs. 0.736). However, for younger AD subjects,
aROC values were significantly higher for VRS-MTA measures (0.920) than for volumetric
measures (0.847). Relative to HP-v, VRS-MTA score was significantly more correlated to
impairment on a range of memory tests and was more associated with progression of
aMCI to AD than HP-v.
Conclusion: Structural MRI with VRS-MTA assessment can serve as a biomarker for
supporting the diagnosis of MCI-AD. Age-adjusted VRS-MTA scores are at least as
effective as HP-v for distinguishing aMCI and AD from CN and for predicting progression
from aMCI to AD. VRS-MTA is convenient for use in the clinic as well as for clinical trials
and can readily be incorporated into a standardized radiological report.
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INTRODUCTION
Recently revised criteria for diagnosing an early clinical stage of
AD (“Mild Cognitive Impairment, or MCI, due to AD”; MCI-
AD) (Albert et al., 2011) and “Prodromal AD” (Sperling et al.,
2011) incorporate biomarkers to increase the certainty of the
diagnosis. One such biomarker, atrophy of the hippocampus
(HP) and other medial temporal lobe (MTL) structures on struc-
tural MRI, increase the likelihood of a neurodegenerative disor-
der, such as AD, as the cause ofMCI. In spite of the widespread use
of MRI scans for the assessment of individuals with various forms
of cognitive impairment, this biomarker is used primarily for
excluding causes of cognitive impairment other than AD, such as
hydrocephalus, vascular and space-occupying lesions. However,
MRI can be used to confirm the presence of neurodegenerative
pathology among patients presenting with MCI and dementia
(Frisoni et al., 2010) and is greatly underutilized for this pur-
pose by clinicians and radiologists. Although prodromal forms
of AD are in a continuum with, and may be clinically indistin-
guishable from what is described as “Probable AD,” current diag-
nostic research standards incorporate a biomarker to support the
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diagnosis of prodromal AD or MCI-AD It is clear that the diag-
nosis of both Probable AD and Prodromal AD/MCI-AD would
be more secure in the presence of a positive biomarker which
provides further evidence of the presence of a neurodegenerative
disease (Albert et al., 2011; Sperling et al., 2011).
Neurodegenerative changes such as atrophy which are char-
acteristic of Alzheimer’s disease (AD), and occasionally of other
dementing diseases, such as Fronto-temporal Lobar Dementia
(FTLD) or Hippocampal Sclerosis, may be detected using vol-
umetric analysis or, more conveniently, using visual rating of
MRI scans. Nevertheless, the incorporation of MRI for confirm-
ing the diagnosis of neurodegenerative disease has yet to receive
widespread utility, in part because of (a) lack of awareness of the
value and accuracy ofMRI for this purpose, (b) automated, quan-
titative volumetric methods for measuring hippocampal volume
are unwieldy, expensive and not easily adapted for routine clinical
use, and (c) the lack of widely accepted age-adjusted norms and
cut-scores for hippocampal volume (HP-v) and medial temporal
atrophy (MTA).
The goal of this study was to evaluate user-friendly methods
to evaluate structural MRI scans and to provide appropriate age-
adjusted cut scores for both visually ratedMTAmeasures andHP-
v structures, which best distinguish normal elderly subjects from
those who have AD. Accordingly, we compared hippocampal vol-
umes (HP-v) to a refinement of the semiquantitative visual rating
method, initially developed by Scheltens et al. (1995). This new
visual rating system for assessing medial temporal atrophy (VRS-
MTA) (Duara et al., 2008; Urs et al., 2009) provides a total MTA
score by combining atrophy levels in individual medial temporal
structures, including the HP, the entorhinal cortex (ERC), and the
perirhinal cortex (PRC). We established appropriate age-related
cut-offs for both volumetric measures of the HP and VRS-MTA
measures, which correctly classified 70–80% of cognitively nor-
mal [CN] subjects without cognitive impairment. We chose these
levels of specificity because at least 20–30% of CN subjects are
known to harbor the pathology of AD on post-mortem evalua-
tion (Morris, 2006). We then compared the accuracy of these two
methods for distinguishing CN from subjects with aMCI and AD,
the associations of these two measures with neuropsychological
measures of cognition and the ability to predict progression from
aMCI to dementia.
METHODS
SUBJECT RECRUITMENT
The current sample was recruited from a group of 273 subjects
(107 CN, who were enrolled in the Florida Alzheimer’s Disease
Research Center Clinical Core (FADRC-CC) in Miami Beach
FL between 2005 and 2009 (Duara et al., 2010). Subjects were
diagnosed as cognitively normal (CN) or having amnestic MCI
(aMCI) or dementia. The study was approved by the Institutional
Review Board at Mount Sinai Medical Center, Miami Beach, and
the University of South Florida, Tampa. All subjects or a legal
representative provided informed consent.
EVALUATIONS
The following were completed on all subjects: (1) full clini-
cal history, obtained from a reliable informant; (2) neurological
evaluation; (3) psychiatric evaluation, including administration
of the Geriatric Depression scale (Sheikh and Yesavage, 1986)
and the Neuropsychiatric Inventory (Cummings et al., 1994); (4)
Clinical Disease Rating scale (CDR-SB; Morris, 1993); (5) Mini-
Mental State Examination (MMSE; Folstein et al., 1975); (6) a
neuropsychological test battery, as described below; (7) Unified
ParkinsonDisease Rating Scale (UPDRS,motor section; Fahn and
Elton, 1987) which has been documented as a sensitive tool for
quantifyingmotor dysfunction and parkinsonism in patients with
various forms of MCI and dementia.
Cardiovascular Risk (CVR) Score was calculated as the sum
of 10 independent risk factors (14) selected from the National
Alzheimer’s Coordinating Center (NACC) Uniform Data Set
(UDS) Subject Health History assessment protocol (Appel et al.,
2009).
DIAGNOSTIC PROCEDURES
DETERMINING A CONSENSUS DIAGNOSIS FOR COGNITIVELY
NORMAL, DIFFERENT MCI SUBTYPES AND DEMENTIA
The physician assigned a cognitive diagnosis of CN, MCI, or
Dementia, as described previously (Duara et al., 2010). Briefly,
the PhyDx was based on the subject’s entire clinical history and
functional status, which was derived from the history itself, CDR
rating, functional activity questionnaire, MMSE score and sub-
scores, taking into account the subjects’ educational and cultural
background, sensory (especially visual and hearing) and motor
deficits, language and speech disorders, medical and psychiatric
conditions and the perceived reliability of the informant. In
addition to the physician’s diagnosis, an independent neuropsy-
chological diagnosis was rendered by a neuropsychologist.
NEUROPSYCHOLOGICAL DIAGNOSIS (NPDx)
All neuropsychological tests were administered in the sub-
jects’ native language (English or Spanish) and compared to
age and education adjusted normative data, as described pre-
viously (Loewenstein et al., 2009). The tests included all of
those outlined in the NACC protocol (Beekly et al., 2007), as
well as additional tests, including the Three Trial Fuld Object
Memory Evaluation (FOME; Fuld, 1981), and the Hopkins
Verbal Learning Test-Delayed Recall (HVLT; Benedict et al.,
1998). Memory measures were: the FOME, HVLT, and Delayed
Visual Reproduction of the Wechsler Memory Scale-R (Wechsler,
1987). Non-memory tests included: category fluency (Monsch
et al., 1992), letter fluency (language; Monsch et al., 1992),
Block Design-WAIS-III (visuospatial; Wechsler, 1997), Trails B
(Executive; Army Individual Test Battery, 1944), and Similarities-
WAIS-R (Executive; Wechsler, 1997). Neuropsychological classi-
fication were made as follows: (a) a test score of 1.5 SD or greater
below expected normative values on any single test for MCI syn-
dromes; and (b) 2.0 SD or greater below expected normative
values in one memory and one non-memory test for dementia
(corresponding to NINCDS-ADRDA criteria; (McKhann et al.,
1984). Nomenclature used for NPDx was Normal, Non-Amnestic
MCI (naMCI; single or multi-domain), amnestic MCI (aMCI;
single or multi-domain) and Dementia.
ALGORITHMIC CONSENSUS COGNITIVE DIAGNOSES (AlgDx)
An algorithmic approach to consensus diagnosis (Duara et al.,
2010) combined the PhyDx with the NPDx, as follows: (a) a
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PhyDx and a NPDx of Normal received an AlgDx of cognitively
normal (CN); (b) a PhyDx diagnosis ofMCI and a NPDx of aMCI
received an AlgDx of aMCI; (c) a PhyDx of dementia and a NPDx
of aMCI or Dementia received an AlgDx of Dementia. Patients
diagnosed with aMCI met Petersen criteria for MCI (Petersen
et al., 1999). Probable AD was diagnosed according to National
Institute of Neurological and Communicative Disorders and
Stroke (NINCDS)–Alzheimer’s Disease and Related Disorders
Association (ADRDA) criteria for AD (McKhann et al., 1984) and
the criteria set forth by the National Alzheimer’s Coordinating
Center.
MRI Scans were acquired using a proprietary 3-D volu-
metric protocol on a Siemens Symphony, 1.5 Tesla machine
(Iselin, NJ) or a GE 1.5 T machine, using proprietary three-
dimensional magnetization-prepared rapid-acquisition gradient
echo (Siemens) or the three-dimensional spoiled gradient recalled
echo (General Electric) sequences;MRI scans were acquired in the
coronal plane, and contiguous slices with thickness of 1.5mm or
less were reconstructed.
VOLUMETRIC ANALYSIS OF BRAIN MRIs
Volumetric analysis is performed using Individual Brain Atlas
and Statistical Parametric Mapping (IBASPM; Alemán-Gómez
et al., 2006). In IBAPSM, the volume of brain regions is calcu-
lated after normalization or spatial transformation to Montreal
Neurological Institute (MNI; McGill University, 2009) templates.
The scans are segmented into three types of tissue in each hemi-
sphere: gray matter, white matter, and cerebrospinal fluid. An
individual brain atlas for each subject is created with the trans-
formation matrix obtained from the normalization step, and
anatomical automatic labeling (AAL) to specify 116 regions.
Hippocampal volume (HP-vol) was calculated as the ratio of the
volume of eachHP (right and left) to the total intracranial volume
(Shen et al., 2011).
VISUAL RATING METHODS ASSESSING BRAIN MRIs
The scope and utility of Scheltens’ system was expanded by Duara
et al. (2008) and Urs et al. (2009), to provide reliable visual rat-
ings of individual MTL regions, i.e., hippocampus (HPC), ERC,
and PRC. Reliability and accuracy were achieved using very thin
coronal slices (1.2 to 1.5mm thickness), perpendicular to the AC-
PC line and intersecting the mammillary bodies (Urs et al., 2009).
We have previously reported excellent inter-rater reliability for
measuring individual MTL structures; kappa values among two
raters ranged between 0.75 and 0.94 for inter-rater reliability and
0.87 and 0.93 for intra-rater reliability. (Urs et al., 2009). With
VRS-MTA, semi-quantitative assessments of atrophy of the HP,
ERC, and PRC were assigned as follows: a score of Grade 0 corre-
sponded to no atrophy, Grade 1 to minimal atrophy, Grade 2 to
mild atrophy, Grade 3 to moderate atrophy and Grade 4 to severe
atrophy (Figure 1). The VRS-MTA program provides a library
of drop-down images, depicting the anatomical boundaries of
these structures as well as each grade of atrophy for the ERC, HP,
and PRC.
ApoE genotype was determined using standard methods
(Wenham et al., 1991). ApoEε4 frequencies were subsequently
calculated for each diagnostic group.
FIGURE 1 | Visual rating scale. Image depicting four degrees of atrophy in
Hippocampus and Entorhinal cortex according to visual rating scale where
0 = no atrophy, 1 = minimal atrophy, 2 = mild atrophy, 3 = moderate
atrophy and 4 = server atrophy (Score shown corresponds to both
structure).
DERIVING CUT-OFFS FOR HP-VOL AND VRS-MTA VALUES FOR
DIFFERENT AGE GROUPS AND BOTH BRAIN SIDES
To derive cut-scores for HP-vol (measured as percentage of
intracranial volume) for the older CN group we used the scores
of 20 subjects, aged 76 years and above (mean age = 79.64 years;
SD = 3.2 years range = 76–90 years), who had an algorithmic
diagnosis of CN. The cut-off scores for the lowest 20% (liberal cut
score ≤0.0249%) and 30% (conservative cut score ≤0.0224%) of
HP-vol, for each side, which was then used to identify hippocam-
pal atrophy for all diagnostic groups aged 76 or greater. Similarly,
we determined the approximate cut score (range of 0–12 points
for each side), for highest 20–30% (liberal cut score ≥4) or 30–
40% (conservative cut score ≥5) of combined HP, ERC, and PRC
ratings on the left and right sides. These cut scores were then used
to identify threshold levels of MTA for all diagnostic groups, aged
76 years or greater, separately for the right and left sides in each
subject.
To derive a cut-score for the younger CN group, we took
the scores of 87 cognitively normal individuals aged 63–75 years
(mean age = 68.33 years; SD = 3.2 years) and used a simi-
lar procedure as for the older CN. The derived cut scores for
HP-v (liberal cut score ≤0.027; conservative cut score ≤0.0257)
and VRS-MTA ratings (liberal cut score ≥2.0; conservative cut
score ≥3) for the right and left sides for each subject. In addition,
so as to identify localized atrophy within the medial temporal
region on each side, independent of the total VRS-MTA score,
we determined the highest VRS scores for the right and left HP
and ERC for each subject. For these measures a liberal (≤1.5) and
a conservative (≤2.0) cut score were determined that would clas-
sify not more than 20 or 33% of both young and old CN group
as having abnormal atrophy. These cut scores were also applied to
subjects diagnosed with amnestic MCI and dementia.
LONGITUDINAL EVALUATION PROCEDURES
A total of 72 of the 103 subjects had at least one-annual follow-up
evaluation (mean = 33.1 months; SD = 14.1 months), includ-
ing neurological, psychiatric and neuropsychological evaluations,
and re-diagnosis by the AlgDx. The mean age of this sample
was 76.8 (SD = 5.8 years) and mean MMSE scores of were 26.1
(SD = 2.4) making the sample comparable to the aMCI patients
who were originally diagnosed at baseline.
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STATISTICAL ANALYSIS
Group comparisons of demographic variables across three study
groups were analyzed using analyses of variance (ANOVA) or chi-
square tests, as appropriate. Post-hoc tests of means were exam-
ined by the Tukey-Kramer procedure at p < 0.05. Comparative
analyses of VRS-MTA and HP-v measures were assessed using
receiver operator (ROC) curves. HP-v and MTA-VRS scores were
correlated to a broad array of cognitive measures among mem-
ory impaired patients. Comparisons between correlation coeffi-
cients were tested statistically using SISA binomials (Uitenbroek,
1997). Finally, differences in progression rates across groups were
assessed using chi-square procedures.
RESULTS
DEMOGRAPHICS
In the entire sample of subjects (age range = 63–93 years; mean
age = 75.0 ± 7.2 years) there were statistically significant demo-
graphic differences between CN, aMCI, and AD groups, with
regards to age, gender and educational attainment as well as on
MMSE scores [F(2, 269) = 172.05; p < 0.001] (Table 1). Post-hoc
tests revealed that CN patients were younger, better educated, had
higher MMSE scores and were more frequently female compared
to the other two groups. AD subjects were older and had lower
MMSE scores than aMCI subjects. There were significant group
differences with regards to Spanish vs. English-speaking subjects
or percentage of subjects carrying one or more ApoE 4 allele.
As indicated in Table 1, CN subjects scored higher than aMCI
and AD subjects on all neuropsychological measures, and demon-
strated less atrophy in comparison to aMCI and AD subjects
on VRS-MTA and HP-v scores. AD subjects had more atrophy
than aMCI subjects on VRS-MTA and HP-v measures, as well as
impairment on all neuropsychological measures, with the excep-
tion of the Block Design test, in which there was no difference in
scores between AD and aMCI subjects.
PERFORMANCE OF VRS-MTA vs. HP-v
For the discrimination of amnestic MCI from CN, in both the
younger and older age groups, there was no difference in the
areas under receiver operating curve (aROC) between HP-v mea-
sures and VRS-MTA measures (Z = 1.26; p < 0.27) (Table 2).
For the discrimination of AD from CN, among the younger
age group (63–75 years), VRS-MTA performed better than HP-v
(aROC: 0.92 vs. 0.847, p < 0.046). The corresponding sensitiv-
ity/specificity values for VRS-MAT and HP-v were: 89.2/82.1%
and 75.7/82.1% for the more liberal cutoffs described in the
methods. There was no difference between the performance of
VRS-MTA and HP-v in the older group, for the classification of
AD vs. CN. Considering the correct age-associated cut-offs for
impairment for the total sample, 63% of those subjects who did
not meet criteria for impairment using HP-v, did meet criteria for
impairment using VRS-MTA, and conversely, only 30% of those
who were VRS-MTA negative were HP-v positive.
CORRELATIONS WITH COGNITIVE MEASURES
In a combined group of aMCI and AD subjects, who had ade-
quate cognitive testing data, both HPv and VRS-MTA measures
were strongly correlated with scores on various memory tests and
with the category fluency test (a measure of speed of search from
semantic lexicon) (Table 3). Tests of visuospatial function (block
design), processing speed and attention (Trails A) and executive
Table 1 | Demographics and MRI measures.
CN (n = 107) aMCI (n = 105) AD (n = 56) f -value
Age 71.1c (5.8) 77.9b (5.3) 79.5a (6.8) 42.59***
Education 15.0a (3.2) 12.4b (3.9) 12.4b (4.1) 16.71***
Gender (Female) 75.7% 50.0% 53.7% X2= 16.93***
Hispanic% 47.4% 48.0% 57.4% X2= 1.64***
ApoE% 24.7% 30.6% 42.9% X2= 4.13 ***
MMSE 29.0a (1.1) 25.9b (2.5) 22.4c (3.1) 172.05***
Fuld OME 25.7a (2.0) 18.9b (4.8) 10.6c (6.5) 195.35***
HVLT-Total Recall 25.3a (4.3) 17.4b (4.5) 13.2c (4.7) 159.48***
HVLT-DEL 9.2a (1.7) 3.7b (2.9) 1.3c (2.2) 258.75***
Semantic interference test (SIT) score 13.3a (2.9) 8.2b (3.2) 3.1c(3.0) 209.04***
Visual reproduction test-delayed 23.0a (7.9) 8.3b (7.2) 3.4c (5.7) 149.08***
Memory for Passages (Delayed) 11.5a (3.5) 5.6b (3.7) 2.2c (3.0) 149.92***
Two Category Fluency 34.2a (7.3) 24.1b (6.2) 17.2c (5.9) 134.24***
Block Design- WAIS-IV 31.5a (9.4) 19.11b (7.9) 18.8b (7.8) 64.39***
Trails A 35.9a (11.3) 54.5b (23.9) 73.5c (33.5) 55.04***
Trails B 95.1a (48.2) 199.4b (88.6) 254.1c (73.7) 106.58***
HP-v (most impaired side) 0.00275a (0.0003) 0.00240b (0.004) 0.00208c (0.005) 60.3***
VRS-MTA score (most impaired side) 1.7a (1.8) 4.2b (2.7) 6.9c (3.3) 81.31***
CN, Cognitively normal; aMCI, amnestic cognitive impairment; MMSE, Mini-mental status exam; HVLT, Hopkins verbal learning test; HP-v, Hippocampal volume;
VRS-MTA, Visual rating scale-mdial temporal atrophy. *** p < 0.001; means with different superscripts are statistically different at p < 0.05 by the Tukey-
Kramer test.
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Table 2 | HP-v and VRS-MTA measures in the classification of subjects with Amnestic MCI and Alzheimer’s disease.
Diagnostic comparison Sensitivity/Specificity aROC for Sensitivity/Specificity aROC for VRS- Comparison of aROCs
and age group (%) for HP-v HP-v measure (%) for VRS-MTA MTA measure for Hp-v and VRS-MTA
AMNESTIC MILD COGNITIVE IMPAIRMENT VERSUS ELDERLY NORMAL
63–75 years (n = 60) 35.0/82.1 0.652 (SE = 0.06) 55.0/82.1 0.723 (SE = 0.06) Z = 1.38; p > 0.26
76+ years (n = 45) 60.0/81.6 0.764 (SE = 0.05) 51.1 /78.2 0.736 (SE = 0.05) Z = 0.60; p > 0.54
ALZHEIMER’S DISEASE VERSUS ELDERLY NORMAL
63–75 years (n = 37) 75.7/82.1 0.847 (SE = 0.05) 89.2/82.1 0.920 (SE = 0.03) Z = 2.00; p < 0.046
76+ years (n = 19) 63.2/81.6 0.713 (SE = 0.08) 68.4/78.2 0.853 (SE = 0.04) Z = 1.66; p < 0.10
HP-v, hippocampal volume; VRS-MTA, Visual rating system- medial temporal atrophy; aROC, Area under the receiver operating curve; AD, Alzheimer’s disease; MCI,
amnestic MCI; CN, Cognitively normal.
Table 3 | Comparative correlations between volumetric and VRS-MTA measures among 129 cognitively impaired patients.
Correlation Correlation Test of difference p-value
with HP-v with VRS-MTA in correlations
coefficients#
Fuld object memory evaluation 0.35*** −0.51*** 2.33 <0.011
HVLT (Delayed Recall) 0.15 −0.29*** 1.91 <0.030
WMS- memory for passages (Delayed Recall) 0.20* −0.36*** 2.27 <0.013
WMS-visual reproduction (Delay Recall) 0.33*** −0.47*** 1.96 <0.027
Two word category fluency 0.31*** −0.32*** 0.14 446
Trails A −0.14 0.07 NA NA
Trails B −0.05 0.11 NA NA
Block-design WAIS-II 0.05 −0.09 NA NA
Similarities WAIS-R −0.10 0.09 NA NA
HP-v, hippocampal volume; VRS-MTA, Visual rating system-medial temporal atrophy. #Difference in correlations tested using SISA polynomials (Uitenbroek, 1997)/
*p < 0.05, ***p < 0.001.
function (Trails B) were not correlated significantly with HP-v
or VRS-MTA imaging measures. In most instances the mem-
ory measures (using the Fuld OME, for example) were more
strongly correlated with VRS-MTA (r = −0.51) than with HP-v
(r = −0.35) (t = 2.33; p < 0.02) (Table 3).
PROGRESSION FROM aMCI TO AD
Among a sample of aMCI subjects (n = 72; mean age = 76.8 ±
5.8 years: educational attainment = 12.83 ± 3.6 years) with ade-
quate follow-up data (mean follow-up period = 33.1 ± 14.1
months) the percentage of progressors vs. non-progressors to
AD was predicted using both stringent and liberal VRS-MTA
cut-off scores (Table 4). Using stringent VRS-MTA criteria, 51%
of aMCI subjects scoring at or above the impairment cut-off
were found to be progressors, as compared to 21% scoring at or
above the impairment cut-off being non-progressors (χ2 = 5.51;
p = 0.019). In contrast, for HP-v 41 % of aMCI subjects scoring
at or above the impairment cut-off were found to be progressors,
as compared to 29% scoring at or above the stringent impairment
cut-offs being non-progressors (χ2 = 1.19; p = 0.28).
DISCUSSION
In this study, we showed that VRS-MTA is superior to volumet-
ric assessment of the HP (HP-v) for distinguishing aMCI patients
Table 4 | VRS-MTA score, HP-v and progression from aMCI to AD.
Progressors Non-progressors Chi-square p-value
to AD
VRS-MTA
score
(Conservative
criteria)
50.7% 20.6% 5.51 0.019
HP-v
(Conservative
criteria)
44.1% 28.9% 1.19 0.275
HP-v, hippocampal volume; VRS-MTA, Visual rating system-medial temporal
atrophy.
and normal elderly controls. When we divided the subjects into
“young-old” (63–75 years) and “older-old” (76 years+) sub-
groups, our previous findings hold true, in much smaller groups
of subjects (Duara et al., 2008; Shen et al., 2011). We have also
shown that VRS-MTA ratings correlate more strongly than do
HP-v withmemorymeasures and CDR ratings (Shen et al., 2011).
In this study, we have additionally provided age-corrected cut-
scores for HP-v and VRS–MTA scores for classifying subjects with
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aMCI and AD and have shown that VRS-MTA scores, but not HP-
v scores in this cohort, were predictors of progression from aMCI
to AD.
The use of structural MRI scans as biomarkers, in association
with clinical criteria, for distinguishing CN subjects from those
with incipient or Probable AD requires the use of age-adjusted
cut- scores for research and for clinical practice. For the first
time, to our knowledge, we have shown that specific age-related
cut-scores for VRS-MTA and HP-v measures can be used for
distinguishing CN from AD subjects. By deriving scores for the
most impaired hemisphere, based upon age-related norms, we
may have further enhanced the overall sensitivity of VRS-MTA.
Indeed, almost two thirds of those subjects who did not meet cri-
teria for impairment usingHP-v, didmeet criteria for impairment
using VRS-MTA, and conversely, less than a third of those who
were VRS-MTA negative were HP-v positive. Thus, each measure
provides unique information, most notably VRS MTA, which
includes independent and additive measures of the HP, ERC,
and PRC.
An advantage of using VRS-MTA over HP-v is that regional
brain volumes are variable across individuals and need to be
normalized by conversion to a ratio of the absolute volume of
the HP to intracranial volume, whereas VRS-MTA has built–in
normalization and thus avoids multiplicative errors inherent in
using ratios of two quantitative variables. From the clinician’s
vantage point, VRS-MTA has the following additional desirable
attributes: (1) measurement and scoring of VRS-MTA is quick
and reliable by the clinician, providing a distinct advantage over
traditional volumetric techniques; (2) HP-v measurements, as
compared to VRS-MTA measurements, require much greater
technical stringency in the acquisition of the MRI scans and
are far more vulnerable to a variety of measurement errors;
(3) HP-v measurements require a technical interface for obtain-
ing quantitative assessment whereas VRS-MTA does not (Duara
et al., 2008; Shen et al., 2011). Although volumetric analysis of
regional brain atrophy can be performed by a variety of pro-
grams which are widely available, they have been used almost
exclusively in research applications, and not in clinical practice.
Currently, measurement of HP-v is inconvenient and expensive
in time and money and technical problems that often occur
during the image acquisition protocol may invalidate the use
of a substantial proportion of MRI scans performed in the
community.
From a biological standpoint it is clear that hippocampal
atrophy is non-specific and that the characteristic pathologi-
cal changes in AD (Braak and Braak, 1985; Braak et al., 2006)
begin outside the HP, with development of neurofibrillary tangles
in the transentorhinal and entorhinal cortex, spreading subse-
quently to the subiculum and CA1 regions of the HP. Subsequent
spread of pathology occurs to limbic, and ultimately to neocor-
tical regions, such as the precuneus, middle frontal gyrus and
posterior cingulate gyrus. The severity of this atrophy, at least in
themedial temporal regions, correlates with the severity of under-
lying AD-related neuropathological changes seen on postmortem
(Jack et al., 2002).
The use of VRS-MTA methodology affords a unique
perspective, not available to those using quantitative HP-v
measures, of the presence and severity of the neurodegener-
ative process in AD. Atrophy of the entorhinal and perirhi-
nal cortices and the HP, widening of the collateral sulcus
and atrophy of the white matter band between the subicu-
lum and the ERC are well known pathological features of AD
and are readily visible on appropriately obtained MRI scans
acquired or reconstructed in the coronal plane in thin, con-
tiguous brain slices. This information often times serves to
confirm the clinical diagnosis, especially in a patient in which
non-neurodegenerative causes of cognitive impairment, such
as cerebrovascular disease or psychiatric conditions are also
under consideration. The absence of confirmatory neurode-
generative findings on the MRI scan alerts the clinician to
alternative causes of impaired cognitive performance, such as
systemic disorders, attention deficit disorders, sleep-apnea syn-
drome, depression, anxiety, and cultural or language related
factors.
The current investigation has the following advantages over
previous studies: (1) Optimal age- related cut-scores for VRS-
MTA and HP-v have been derived for normal subjects and
then applied to aMCI and AD cases; (2) the importance of
frequently-observed asymmetrical atrophy in medial temporal
regions and HP-v volumes has been recognized and incorpo-
rated into the algorithm for distinguishing CN from aMCI and
AD subjects, using either VRS-MTA or HP-v measures (typ-
ically, rather than using the most atrophic side in the algo-
rithm, bilateral regions are combined into a single score). Using
these methods our results indicate that VRS-MTA is at least as
good, and more likely better than using HP-v for distinguish-
ing both younger and older aMCI and AD subjects from CN
subjects. VRS-MTA scores are also better correlated than are
HP-v measures with memory and functional indices. Finally,
VRS-MTA measures are better than HP-v measures in pre-
dicting progression to AD or dementia over a defined period
of time. This suggests that VRS-MTA may provide a clearer
indication of neurodegenerative pathology related to AD than
merely HP-v.
Some of the limitations of using VRS-MTA include the fact
that ratings are based on assessments performed on a single
coronal slice, thereby providing a limited perspective of over-
all brain pathology (this limitation can be easily overcome by
evaluating multiple adjacent coronal slices). In addition, atro-
phy in the medial temporal regions may not be specific to AD,
but in some cases may be indicative of hippocampal sclerosis,
frontotemporal lobar dementias, Lewy body dementia, vascular
dementia, or cognitive impairment (Jack et al., 2002; Barkhof
et al., 2007). Also, a larger and more diverse group of elderly
normals will be required to extend age-related cut-off scores
further than we have been able to do in this study. Age is a
risk factor for AD and other neurodegenerative disorders and
up to 30% elderly adults with underlying brain pathology may
have sufficient cognitive reserve so that they do not present with
cognitive symptoms. Hence, it is likely that among elderly vol-
unteers, who are cognitively normal, substantial AD pathology
is present, which may be reflected in their VRS-MTA scores,
thereby apparently reducing the specificity of VRS-MTA cut-off
scores.
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At present, the primary utility of structural MRI, in the diag-
nosis of disorders causing cognitive impairment, is to rule out
specific pathologies such as pathologies as hydrocephalus, vascu-
lar, inflammatory or demyelinating, and space-occupying lesions
as the cause of the cognitive syndrome, but not for confirming
the presence of AD-like pathology and its severity. Our results
suggest that VRS-MTA, which could readily be incorporated
into the routine assessment of patients presenting with mem-
ory symptoms, will likely assist in strengthening the diagnosis
of AD or ruling it out, thereby improving both sensitivity and
specificity of a clinical diagnosis of probable and prodromal AD.
Moreover, VRS-MTA need not be used exclusively for clinical
purposes; it could also serve as a research tool, especially in
clinical trials when accuracy of the clinical diagnosis is a major
requirement.
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